First GLP-1 weight loss pill in Australia to hit market by end of the year
Australia's Therapeutic Goods Administration has approved the oral GLP-1 weight-loss pill Wegovy, marking the first time an oral version of the drug is available in the country. The pill is expected to increase demand for weight-management treatments as it offers a more convenient alternative to weekly injections.
Why it matters
The approval signals a shift in obesity treatment accessibility and potential market growth for pharmaceutical companies like Novo Nordisk.
Save You have reached your maximum number of saved items.
Remove items from your saved list to add more.
Gift Gift icon 0 / 3 No gift articles left
You've used all of your gift articles. 3 more will become available on the 1st of every month.
Share A A A A GLP-1 weight-loss tablet has been approved in Australia for the first time, and is expected to lead to a surge in demand for the sought-after peptide that could hit the market by the end of this year.
The Therapeutic Goods Administration (TGA) approved Novo Nordisk’s Wegovy (semaglutide) pill on Tuesday evening, following similar endorsements in the UK and the US.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in